Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Mussolini's summer villa on Adriatic coast sold for €1.2 million- 6 Hints to Upgrade Your Appeal, In addition to Your Outlook
- Why doing good also makes us feel good, during the holidays and beyond
- Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
- He walked on the moon in 1972. This is his advice for the Artemis II astronauts.
- RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
- Drones haven't won the fight in Ukraine. That matters as the West learns new ways of war.
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
- She just became the first wheelchair user to travel to space
